ACADIA Pharmaceuticals (ACAD) Stock Forecast for 2025, 2026, 2027. Sell or Buy Prediction







Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency

April 23, 2025 Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency

What defines a successful crypto expert? The amount of money earned, the number of luxury cars and international real estate? The presence of…
Features of exchanging USDC ERC20 to Bank Transfer

March 12, 2025 Features of exchanging USDC ERC20 to Bank Transfer

You can use electronic exchange services if you need to exchange the digital asset USDC ERC20 to Bank Transfer. It is not recommended…
Why Stock Caps Matter When Building a Diversified Portfolio

February 19, 2025 Why Stock Caps Matter When Building a Diversified Portfolio

Most investors who want to expand their investment options put their money in different asset types and industries across many areas in the…
Top 5 Coins for the Maximum Passive Income from Staking by 2024

February 5, 2025 Top 5 Coins for the Maximum Passive Income from Staking by 2024

Staking is one of the ways that is now being used as a secure and profitable way to earn money without doing anything…
Trading Stocks With AI: A Modern Approach

January 21, 2025 Trading Stocks With AI: A Modern Approach

The stock market can feel overwhelming, especially with its constant ups and downs. Trading stocks with AI is revolutionizing how investors analyze trends,…

ACADIA Pharmaceuticals (ACAD) Stock Forecast for 2025, 2026, 2027. Sell or Buy?

Updated: May 15, 2025 (21:43)

Sector: Healthcare

The share price of ACADIA Pharmaceuticals Inc. (ACAD) now

Latest session on the 14th of May for
ACADIA Pharmaceuticals Inc. is negative
Trading Volume: 1895094
Open: 17.12 /  High: 17.62 /  Low: 17.04
Current value: $17.16
What analysts predict: $24.37
52-week High/Low: $17.62 / $14.45
50-Day Moving Average: $16.07 — support level today
200-Day Moving Average: $16.67 — support level today

News Impact Analyzer

Full report
This Week
Bearish Impact: 5 News: 1
Previous Week
Bullish Impact: 5 News: 2 (2/0/0)
Two Weeks Ago
Na Impact: Na News: Na
Three Weeks Ago
Na Impact: Na News: Na

Analysts predictions

Full report
This Week
Bullish Opinions: 1 (1/0/0)
Previous Week
Neutral Opinions: Na
Two Weeks Ago
Neutral Opinions: Na
Three Weeks Ago
Neutral Opinions: Na

Analyzing the Most Important ACAD news

Acadia Pharmaceuticals: Major Stakeholder Sale of 43.6M Shares Filed

May 09, 2025
Trend: Bearish
Influence: 7
The filing to sell a large block of shares by stockholders creates a bearish sentiment as it may indicate insider confidence issues or potential downward pressure on the stock price. A sale of this magnitude could also dilute ownership value, leading to heightened market scrutiny and short-term volatility for ACAD shares.

ACADIA Targets Robust Growth with $244M Revenue in Q1, Driven by DAYBUE and NUPLAZID Success

May 07, 2025
Trend: Bullish
Influence: 8
The strong Q1 revenue growth of 19%, driven by key drugs like DAYBUE and NUPLAZID, signals solid operational performance and demand sustainability. Continued progress with Prader-Willi trial data adds to optimism. This positive development can drive investor confidence, potentially boosting stock prices in the short term, given its significant impact on market perception and future projections.

Acadia Pharma Surpasses Expectations with Strong Q1 Earnings and Revenue Growth

May 07, 2025
Trend: Bullish
Influence: 7
Acadia Pharma's Q1 results beat both EPS and revenue forecasts, showcasing impressive growth in NUPLAZID sales. The +0.24% share increase indicates positive investor sentiment. This performance underscores strong operational momentum, likely bolstering the stock price moderately in the near future, especially if growth trajectories sustain.

Historical and forecast chart of ACADIA Pharmaceuticals stock

The chart below shows the historical price of ACADIA Pharmaceuticals stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the ACADIA Pharmaceuticals stock price can be found in the table below.

Long-term forecasts by years.

ACADIA Pharmaceuticals Inc. Analysts predictions review

ACADIA Pharmaceuticals is poised for growth, driven by strategic pipeline diversification and expansion into underserved therapeutic areas. The focus on regulatory approvals for broader indications, combined with strong R&D alliances, enhances its revenue potential. Operational efficiencies and cost management further support margin expansion, mitigating risks from elevated R&D spending. Favorable regulatory tailwinds and growing institutional interest add to the stock's upside momentum, signaling robust investor confidence and potential for continued valuation increases.

ACADIA Pharmaceuticals: Catalysts Driving Growth and Strategic Expansion

Trend: Bullish
May 13, 2025

ACADIA Pharmaceuticals is demonstrating significant progress across multiple operational fronts, signaling a promising outlook for its stock. The company’s expansion into new indications for existing drug assets represents a critical strategic initiative. By pursuing FDA approvals for broader applications, ACADIA aims to solidify its revenue base and mitigate reliance on a single product, potentially driving valuation higher in the near term. The author emphasizes the importance of precision in execution during this approval process as a key determinant of stock momentum.

Pipeline Diversification and Market Opportunities

ACADIA’s diversification of its drug pipeline reflects management’s focus on targeting underserved therapeutic areas, which could provide substantial market opportunities. Leveraging its successful track record in neurological conditions, the firm is expanding into adjacent fields, improving its competitive positioning. The author highlights that these developments reduce the risks associated with product-specific revenue streams, thus enhancing investor confidence.

Furthermore, the company’s strategic partnerships and acquisitions continue to strengthen its R&D capabilities and commercialization potential. These collaborative efforts position ACADIA to capitalize on innovation while benefiting from external expertise, adding a layer of operational synergy. If executed effectively, this approach can act as a growth multiplier, giving the stock an upward bias.


Analyst: Bret Jensen
( Followers: 51021
Articles: 4590 )

Acadia Pharmaceuticals Poised for Growth Amid Strategic Momentum and FY2024 Gains

Trend: Bullish
Mar 02, 2025

Acadia Pharmaceuticals has demonstrated robust performance by leveraging its strong market position in the neuroscience space and delivering solid revenue growth. The company’s focus on expanding its product pipeline, notably in areas with significant unmet medical needs, reflects an aggressive strategy to sustain momentum and drive long-term shareholder value.

Pipeline Development and Strategic Positioning

One critical driver behind ACAD's outlook is its advanced-stage drug candidates and their potential upcoming approvals. The commercialization of these assets could be transformative in propelling earnings and enhancing market penetration, particularly in the mental health and central nervous system (CNS) segments.

The author emphasizes that cost management and operational efficiencies have also played a pivotal role in achieving profitability. This operational discipline bodes well for margin expansion, offsetting near-term risks associated with increased R&D expenditures as the company invests in its pipeline.


Analyst: Bret Jensen
( Followers: 50843
Articles: 4538 )

Acadia Pharmaceuticals: Strong Progress Signals a Strategic Shift to 'Buy'

Trend: Bullish
Feb 13, 2025

A critical driver for Acadia Pharmaceuticals' improving outlook is its continued progress in expanding its key product portfolio. The company has demonstrated meaningful advancements in leveraging its existing pipeline, with particular emphasis on regulatory approvals that enhance its revenue growth potential. This expansion fortifies its market presence and is expected to act as a catalyst for top-line growth in the near-term.

Another factor underpinning the upgraded outlook is the management's ability to execute on operational efficiencies. Efforts to control costs without compromising innovation signify a sustainable pathway towards profitability. The impact of these measures is likely to strengthen investor confidence, which would further buoy the stock price.

Regulatory and Market Tailwinds Strengthen Near-Term Prospects

Additionally, a favorable regulatory environment and increased adoption for key treatments stand out as significant tailwinds. These developments not only minimize potential downside risks but also create an environment conducive to long-term growth. Market dynamics appear supportive, enhancing the probability of continued stock price appreciation.

Lastly, analysts, including the author, point to catalysts in the form of increased institutional investment. Investor sentiment has shifted markedly, signaling broader enthusiasm about the company’s growth trajectory. This trend may further accelerate demand for the stock, driving momentum in its valuation.


Analyst: Edmund Ingham
( Followers: 13005
Articles: 931 )
Nov 11, 2024
Acadia Pharmaceuticals: Catalysts Driving Renewed Investor Confidence
Trend: Bullish

Acadia Pharmaceuticals' recent performance has been underpinned by encouraging developments in drug approvals and expansion efforts. The company’s flagship product, Nuplazid, has secured regulatory backing for expanded indications, demonstrating strong commercial potential and establishing a competitive moat in its target markets. These approvals, alongside management's proactive approach to broadening the product pipeline, are clear signals of sustainable revenue growth over the medium term.

Importantly, Acadia’s strategic focus on internal pipeline development shows impressive traction. Key late-stage clinical trials have yielded promising results, increasing the likelihood of bringing additional high-margin therapies to the market. This not only diversifies Acadia’s revenue base but also materially de-risks its business model from over-reliance on a single product.

The Role of Strategic Partnerships and Market Positioning

The company’s emphasis on forging strategic partnerships has further strengthened its market positioning. Collaborations with leading healthcare institutions and research organizations provide not only a competitive advantage but also cost-efficiency in securing innovation and navigating regulatory barriers. Additionally, Acadia's proactive stance in tapping into underserved markets points toward both growth potential and resilience amid competitive pressures.

Finally, the financial outlook appears reinforced by disciplined capital allocation. Acadia demonstrates improved operating efficiency, reducing cash burn while maintaining sufficient liquidity to fund ongoing R&D initiatives. Investors are likely to interpret these measures as a foundational step for long-term shareholder value creation, mitigating concerns over future dilution risk.

Analyst: Bret Jensen
( Followers: 50649
Articles: 4506 )
Aug 26, 2024
Acadia Pharmaceuticals: Mixed Milestones as Nuplazid Shines While Daybue Faces Challenges
Trend: Neutral

Nuplazid’s strong performance in Q2 demonstrates its potential as a reliable revenue driver for Acadia Pharmaceuticals. The author attributes its continued growth to robust demand in the Parkinson’s disease psychosis space, where competitive pressures remain limited, solidifying its position as a core contributor to the firm's financial stability.

Strategic Product Performance: Opportunities and Risks

However, Daybue’s disappointing performance is a notable challenge, as it fails to meet market expectations for growth in the Rett syndrome space. The underwhelming results suggest weak market uptake or potential execution issues, raising concerns about management’s ability to expand in this high-growth segment.

Operational cost management emerged as a key factor impacting profitability, with spending levels notably higher due to the dual commercialization efforts for Nuplazid and Daybue. While this strategy supports long-term growth ambition, it strains near-term margins and could weigh on investor sentiment.

Finally, the author underscores that the company’s reliance on a narrow portfolio remains a medium-term risk. Acadia’s future growth will depend on diversification efforts or ongoing success from its flagship drugs to mitigate volatility in revenue streams.

Analyst: ONeil Trader
( Followers: 8985
Articles: 876 )
Jun 23, 2024
Acadia Pharmaceuticals: Positioned for Growth Amid Renewed Opportunities
Trend: Bullish

Acadia Pharmaceuticals' recent movements suggest a renewed potential for upward momentum, underpinned by core strategic drivers. The company's strengthened focus on its commercial pipeline, with particular emphasis on its flagship drug Nuplazid, showcases promising growth potential in its primary indications. The continued expansion into other therapeutic areas, such as Rett syndrome, provides diversification to the revenue base, which is significant for mitigating risks associated with over-reliance on one product.

Key Catalysts Supporting Positive Momentum

The financial performance, particularly improving quarterly results, reflects operational efficiency and effective resource allocation. This is crucial in building investor confidence, especially in a volatile sector like biotechnology. Additionally, Acadia's forward momentum in exploring partnerships or M&A opportunities suggests strategic positioning to drive both revenue and market footprint growth. If executed effectively, such initiatives could lead to near-term valuation boosts.

The regulatory environment remains a decisive factor, with potential FDA approvals serving as major catalysts for stock movement. However, any delays or issues in this area could pose significant risks. Finally, the company’s balance sheet health, coupled with robust R&D investment, underscores its preparedness for sustained long-term growth, even as it seeks to capitalize on imminent market opportunities.

Analyst: Bret Jensen
( Followers: 50649
Articles: 4506 )
Jun 06, 2024
Acadia Pharmaceuticals: Unlocking Growth Through CNS Portfolio Expansion
Trend: Bullish

Acadia Pharmaceuticals is poised for significant growth driven by its flagship products Nuplazid and Daybue within the Central Nervous System (CNS) treatment market. Nuplazid, a key treatment for Parkinson's disease psychosis, continues to exhibit strong sales momentum, bolstered by increasing physician adoption and expanding insurance coverage. This stability in revenue generation positions the drug as an essential contributor to near-term cash flows.

Expanding Opportunities Through Product Innovation

Daybue, recently approved for Rett syndrome, marks a pivotal step in Acadia's diversification strategy within rare CNS disorders. Analysts, including the author, view its market penetration as a transformative growth avenue, with the potential to drive a substantial uptick in the company's top line as the product gains traction post-launch.

Additionally, Acadia's pipeline of innovative CNS-focused therapies underscores the company's long-term growth potential. The emphasis on addressing unmet clinical needs within niche CNS segments strengthens Acadia’s positioning as a key player in this therapeutic domain, while providing a hedge against revenue concentration risks presented by its core products.

Finally, the company’s commitment to operational discipline, reflected in controlled costs and revenue allocation to R&D, enhances its ability to navigate market pressures effectively. This operational efficiency ensures that Acadia can sustain its growth trajectory while maintaining margin stability, creating strong tailwinds for the stock's performance.

Analyst: Myriam Alvarez
( Followers: 2190
Articles: 243 )
Mar 13, 2024
Assessing Acadia's Prospects Amid Pimavanserin's Setback and Market Adjustments
Trend: Bearish

The clinical setback of Pimavanserin, Acadia’s flagship drug for expanded indications, serves as a critical blow to investor confidence. This development diminishes the company's near-term growth prospects, given the heavy reliance on the drug as a revenue driver beyond its existing approval for Parkinson’s disease psychosis. The author highlights that the market's negative sentiment is justified in the context of reduced pipeline potential and increased competition.

Key Drivers and Implications for ACAD's Valuation

Acadia’s future hinges significantly on the diversification of its pipeline amidst this setback, as referenced by the author. While there are promising early-stage assets in development, the prolonged timelines and uncertain success rates could delay meaningful contributions to revenues and lead to investor caution in the short to medium term.

The current competitive landscape in neurological and psychiatric therapeutics further compounds pressure on ACAD. Competitors advancing complementary treatments without such clinical hurdles are poised to erode the company’s market share and exacerbate challenges to maintaining growth momentum.

Finally, heightened market volatility and investor aversion to risk amplify the sensitivity of ACAD’s stock to negative news. This underscores a critical need for management to restore confidence through either successful pipeline milestones or strategic partnerships, a factor well-emphasized in the analysis.

Analyst: Stephen Ayers
( Followers: 7833
Articles: 798 )

Comprehensive Analysis of ACADIA Pharmaceuticals (ACAD) Stock Market Performance


Our multifaceted analysis of ACADIA Pharmaceuticals's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:

  • When should I take profit in ACADIA Pharmaceuticals stock?
  • When should I record a loss on ACADIA Pharmaceuticals stock?
  • What are analysts' forecasts for ACADIA Pharmaceuticals stock?
  • What is the future of ACADIA Pharmaceuticals stock?

We forecast ACADIA Pharmaceuticals stock performance using neural networks based on historical data on ACADIA Pharmaceuticals stocks.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, specializes in the development and commercialization of small molecule drugs designed to meet unmet medical needs in diseases of the central nervous system.

ACADIA Pharmaceuticals Inc. News influencing stock rates

As of now, Panda has combed through 3 news items directly related to ACAD from the last 30 days. Out of these, 2 clearly showcase a bullish trend, while 1 display bearish tendencies, and 0 events are neutral.

The strength of the bullish trend outpaces the bearish sentiments by 2 times, indicating that the news backdrop is positively influencing the company’s stock price in the current outlook.

The news analyzed fell within the period from May 07, 2025, to May 09, 2025.

βeta
Feb 26, 2025

Acadia Pharma EPS Surpasses Expectations, Revenue Misses Target

Trend: Neutral
Influence: 6
While Acadia's better-than-expected EPS is a positive signal, the revenue miss tempers broader investor enthusiasm. The 32% annual revenue growth highlights strong long-term potential, but near-term stock movements may remain muted. Overall, mixed results lead to a balanced outlook with moderate impact on the stock's short-term price trajectory.
Feb 25, 2025

Acadia Pharma Set to Report Q4 Earnings: Expecting Solid Growth

Trend: Bullish
Influence: 8
The positive revenue growth forecast (+18.2% Y/Y) and a strong EPS consensus signal robust performance expectations for Acadia Pharma. These optimistic projections could boost investor sentiment and drive the stock price upward in the short term, particularly given the healthcare sector's sensitivity to earnings results.
Jan 14, 2025

Acadia Forecasts Billion-Dollar Breakthrough by 2025

Trend: Bullish
Influence: 8
Acadia Pharmaceuticals' projection of surpassing $1B in sales by 2025 for Nuplazid and Daybue signals strong future growth potential. This bullish outlook reflects confidence in product performance and market demand. The emphasis on revenue milestones can bolster investor sentiment, increasing the likelihood of stock price appreciation as the company edges closer to these financial targets.
Dec 31, 2024

Wall Street Turmoil: ACADIA Pharmaceuticals Shines Amidst Decline

Trend: Bullish
Influence: 7
ACADIA Pharmaceuticals (ACAD) is highlighted as one of the biggest gainers, suggesting positive momentum against a backdrop of broader market declines. This positions ACAD favorably in investor sentiment, potentially driving more interest and investment in the short term. Despite market volatility, this positive outlier narrative indicates a bullish influence on ACAD's stock price.
Dec 31, 2024

Acadia Pharmaceuticals Joins S&P SmallCap 600 Following Bank Acquisition

Trend: Bullish
Influence: 7
Acadia's inclusion in the S&P SmallCap 600 can enhance its visibility and investor appeal, potentially leading to increased demand for the stock. This is a positive development ('Bullish'), given the prestige and exposure associated with being part of a recognized index. The influence is moderately strong (7), as index inclusions often lead to a rise in stock prices.
Dec 12, 2024

Acadia Sells FDA Voucher for $150M Cash Boost

Trend: Bullish
Influence: 7
Acadia Pharmaceuticals' sale of its FDA voucher for $150M provides a significant cash inflow without diluting shareholder value. This strategic move strengthens the company's financial position, which could be used for further development or operations, thus likely driving positive sentiment among investors and creating a bullish outlook in the short to medium term for ACAD stock.
Nov 26, 2024

Acadia Secures $610M Deal for Essential Tremor Treatment with Saniona

Trend: Bullish
Influence: 8
Acadia’s acquisition of global rights to SAN711 through a substantial deal with Saniona positions it strategically within the essential tremor market. The upfront payment and potential milestone payments indicate strong confidence in the candidate's future. This move is likely to boost ACAD's stock by expanding its therapeutic portfolio, reflecting a strong positive momentum in the short-term market perception.
Nov 06, 2024

Acadia Pharma Surpasses Q3 Earnings and Revenue Expectations

Trend: Bullish
Influence: 7
Acadia Pharma's better-than-expected earnings and revenue indicate strong financial health and positive growth momentum. An EPS beat by $0.06 and revenue growth of 18.3% year-over-year typically signal operational efficiency and market demand, likely driving investor confidence. These results can lead to an uplift in stock prices, making the trend 'Bullish' with a strong influence rating of 7.
Nov 05, 2024

Acadia Pharma Earnings: Anticipate Growth Amidst Mixed Analyst Sentiments

Trend: Neutral
Influence: 5
The mixed revisions in both EPS and revenue estimates reflect uncertainty, leading to a neutral trend. Positive revenue growth is expected, but downward revisions in earnings estimates signal caution. The influence level is moderate, as the earnings announcement can provide clarity on Acadia's performance, impacting investor sentiment and potentially stock price volatility.
Nov 05, 2024

Acadia Nets $150M from Sale of FDA Priority Voucher

Trend: Bullish
Influence: 7
Acadia's sale of the Priority Review Voucher for $150M provides a significant cash boost, enhancing its ability to fund commercial operations and R&D. This capital influx, especially in specialized fields like CNS and rare diseases, signals growth potential, making it a bullish indicator. The stock may see positive movement due to this strategic strengthening of financial resources.

Trending Themes in the Healthcare Sector

ACADIA Pharmaceuticals daily forecast for a month

Date Target Pes. Opt. Vol., %
May 17 17.43 17.19 17.75 3.22
May 18 17.58 17.21 17.92 4.14
May 19 17.13 16.73 17.23 3.01
May 20 17.26 16.87 17.63 4.51
May 21 17.30 17.14 17.48 2.00
May 22 17.67 17.32 17.89 3.28
May 23 17.50 17.13 17.74 3.56
May 24 17.47 17.12 17.87 4.38
May 25 17.63 17.32 17.82 2.84
May 26 17.84 17.65 18.02 2.09
May 27 18.04 17.89 18.41 2.87
May 28 18.48 18.08 18.75 3.71
May 29 18.82 18.62 19.10 2.58
May 30 19.34 19.16 19.60 2.30
May 31 19.46 19.01 19.61 3.16
Jun 01 20.00 19.67 20.38 3.60
Jun 02 20.22 20.02 20.45 2.12
Jun 03 20.06 19.85 20.19 1.73
Jun 04 19.61 19.34 19.88 2.80
Jun 05 19.07 18.61 19.45 4.49
Jun 06 19.23 19.12 19.39 1.42
Jun 07 19.49 19.12 19.80 3.55
Jun 08 19.28 19.03 19.53 2.65
Jun 09 19.25 18.95 19.44 2.56
Jun 10 19.75 19.61 19.90 1.45
Jun 11 20.03 19.86 20.29 2.18
Jun 12 19.45 19.10 19.67 2.99
Jun 13 19.62 19.35 19.76 2.10
Jun 14 19.79 19.38 20.20 4.23
Jun 15 19.31 19.19 19.68 2.54

ACADIA Pharmaceuticals Daily Price Targets


ACADIA Pharmaceuticals Stock Forecast 05-17-2025.

Forecast target price for 05-17-2025: $17.43.
Positive dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 3.124%.
Pessimistic target level: 17.19
Optimistic target level: 17.75

ACADIA Pharmaceuticals Stock Forecast 05-18-2025.

Forecast target price for 05-18-2025: $17.58.
Positive dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 3.973%.
Pessimistic target level: 17.21
Optimistic target level: 17.92

ACADIA Pharmaceuticals Stock Forecast 05-19-2025.

Forecast target price for 05-19-2025: $17.13.
Negative dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 2.922%.
Pessimistic target level: 16.73
Optimistic target level: 17.23

ACADIA Pharmaceuticals Stock Forecast 05-20-2025.

Forecast target price for 05-20-2025: $17.26.
Positive dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 4.317%.
Pessimistic target level: 16.87
Optimistic target level: 17.63

ACADIA Pharmaceuticals Stock Forecast 05-21-2025.

Forecast target price for 05-21-2025: $17.30.
Positive dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 1.960%.
Pessimistic target level: 17.14
Optimistic target level: 17.48

ACADIA Pharmaceuticals Stock Forecast 05-22-2025.

Forecast target price for 05-22-2025: $17.67.
Positive dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 3.171%.
Pessimistic target level: 17.32
Optimistic target level: 17.89

ACAD (ACAD) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jun. 19.61 17.85 20.73 13.91
Jul. 18.14 16.75 20.21 17.10
Aug. 17.92 16.93 18.84 10.13
Sep. 18.70 17.13 20.47 16.31
Oct. 18.31 16.85 19.99 15.67
Nov. 18.09 16.62 19.91 16.49
Dec. 17.36 15.90 17.96 11.45

ACADIA Pharmaceuticals forecast for this year


ACADIA Pharmaceuticals Stock Prediction for Jun 2025

An uptrend is forecast for this month with an optimal target price of $19.6113. Pessimistic: $17.85. Optimistic: $20.73


ACADIA Pharmaceuticals Stock Prediction for Jul 2025

An downtrend is forecast for this month with an optimal target price of $18.1404. Pessimistic: $16.75. Optimistic: $20.21


ACADIA Pharmaceuticals Stock Prediction for Aug 2025

An downtrend is forecast for this month with an optimal target price of $17.9227. Pessimistic: $16.93. Optimistic: $18.84


ACADIA Pharmaceuticals Stock Prediction for Sep 2025

An uptrend is forecast for this month with an optimal target price of $18.7024. Pessimistic: $17.13. Optimistic: $20.47


ACADIA Pharmaceuticals Stock Prediction for Oct 2025

An downtrend is forecast for this month with an optimal target price of $18.3096. Pessimistic: $16.85. Optimistic: $19.99


ACADIA Pharmaceuticals Stock Prediction for Nov 2025

An downtrend is forecast for this month with an optimal target price of $18.0899. Pessimistic: $16.62. Optimistic: $19.91


ACADIA Pharmaceuticals Stock Prediction for Dec 2025

An downtrend is forecast for this month with an optimal target price of $17.3573. Pessimistic: $15.90. Optimistic: $17.96



ACADIA Pharmaceuticals (ACAD) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 16.60 15.16 17.70 14.35
Feb 17.05 16.41 18.69 12.18
Mar 19.12 16.88 20.84 18.99
Apr 18.29 16.18 19.11 15.36
May 16.42 14.92 18.10 17.56
Jun 16.25 15.59 16.84 7.38
Jul 17.91 15.84 18.72 15.36
Aug 19.79 19.14 20.47 6.53
Sep 18.43 16.49 19.20 14.11
Oct 17.73 16.62 19.49 14.74
Nov 19.06 17.58 19.86 11.52
Dec 19.15 17.89 21.33 16.16

ACADIA Pharmaceuticals (ACAD) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 18.52 17.52 20.21 13.33
Feb 19.63 17.98 20.75 13.34
Mar 18.42 16.57 20.58 19.47
Apr 17.87 16.37 19.77 17.22
May 17.33 16.19 18.11 10.62
Jun 18.92 17.22 20.65 16.63
Jul 18.32 16.12 19.09 15.55
Aug 20.11 18.96 22.46 15.58
Sep 20.62 19.23 22.51 14.57
Oct 18.40 16.99 20.05 15.28
Nov 18.42 17.32 20.03 13.52
Dec 16.43 15.67 17.07 8.23

ACADIA Pharmaceuticals information and performance

ACADIA Pharmaceuticals Address

3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO, CA, US

Market Capitalization: 2 908 800 000 $

Market capitalization of the ACADIA Pharmaceuticals Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of ACAD shares in the company outstanding by the market price of one share.

EBITDA: 101 665 000 $

EBITDA of ACADIA Pharmaceuticals is earnings before interest, income tax and depreciation of assets.

PE Ratio: 12.73

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: -0.42

Price/earnings to growth

DPS: None

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: None

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: 1.37

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: 0.1
Quarterly Revenue Growth YOY: 0.187
Trailing PE: 12.73

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 34.6

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 2.292

Enterprise Value (EV) /Revenue

EV To EBITDA: 22.46

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 166789000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

FAQ (Frequently Asked Questions about ACADIA Pharmaceuticals Stock)

Should I Buy ACADIA Pharmaceuticals Shares in 2025 year?

The maximum forecasted share price for next year is $19.79, which is $2.63 higher than the current stock price. By investing in ACADIA Pharmaceuticals shares today for a one-year period, you could achieve a profit of 15.33%. With an investment horizon of up to two years, the target share price is $20.62. resulting in a profit of 20.18% ($3.46 per share).

Does ACADIA Pharmaceuticals pay dividends?

No, it does not

Which economic sector do ACADIA Pharmaceuticals's shares belong to?

ACADIA Pharmaceuticals's shares belong to the "Healthcare" sector of economic.

Which other securities belong to the same sector as ACADIA Pharmaceuticals's shares?

You can view all the stocks that are part of the same sector as ACADIA Pharmaceuticals's shares in the Healthcare section.


Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.